DDInter1158 DDInter364
An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease. Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent. Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation of mesalazine within microgranules. In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce the risk of colorectal cancer in conditions like ulcerative colitis is maintained.[A174019,A174022]
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Chlorpropamide is not recommended for the treatment of NIDDM as it increases blood pressure and the risk of retinopathy (UKPDS-33). Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites. Renal and hepatic dysfunction may increase the risk of hypoglycemia.
Mesalazine {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Chlorpropamide
Mesalazine {u} (Compound) causes {v} (Side Effect) Pancytopenia
Pancytopenia {u} (Side Effect) is caused by {v} (Compound) Chlorpropamide
Mesalazine {u} (Compound) causes {v} (Side Effect) Pancytopenia
Pancytopenia {u} (Side Effect) is caused by {v} (Compound) Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Mesalazine {u} (Compound) downregulates {v} (Gene) TIMM9
TIMM9 {u} (Gene) is downregulated by {v} (Compound) Sulfacetamide
Sulfacetamide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Mesalazine {u} (Compound) causes {v} (Side Effect) Pancytopenia
Pancytopenia {u} (Side Effect) is caused by {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Mesalazine {u} (Compound) downregulates {v} (Gene) TIMM9
TIMM9 {u} (Gene) is downregulated by {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Mesalazine {u} (Compound) downregulates {v} (Gene) TIMM9
TIMM9 {u} (Gene) is regulated by {v} (Gene) KCNJ11
KCNJ11 {u} (Gene) is bound by {v} (Compound) Chlorpropamide
Mesalazine {u} (Compound) binds {v} (Gene) PPARG
PPARG {u} (Gene) is bound by {v} (Compound) Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Mesalazine {u} (Compound) binds {v} (Gene) PPARG
PPARG {u} (Gene) is associated with {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Chlorpropamide
Mesalazine {u} (Compound) resembles {v} (Compound) Methyldopa
Methyldopa {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Mesalazine (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Chlorpropamide (Compound)
Mesalazine (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Chlorpropamide (Compound)
Mesalazine (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Glipizide (Compound) and Glipizide (Compound) resembles Chlorpropamide (Compound)
Mesalazine (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Chlorpropamide (Compound)
Mesalazine (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Gliclazide (Compound) and Gliclazide (Compound) resembles Chlorpropamide (Compound)
Mesalazine (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Gliclazide (Compound) and Gliclazide (Compound) resembles Chlorpropamide (Compound)
Mesalazine (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is regulated by KCNJ11 (Gene) and KCNJ11 (Gene) is bound by Chlorpropamide (Compound)
Mesalazine (Compound) binds PPARG (Gene) and PPARG (Gene) is bound by Glipizide (Compound) and Glipizide (Compound) resembles Chlorpropamide (Compound)
Mesalazine (Compound) binds PPARG (Gene) and PPARG (Gene) is associated with type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Chlorpropamide (Compound)
Mesalazine (Compound) resembles Methyldopa (Compound) and Methyldopa may cause a minor interaction that can limit clinical effects when taken with Glipizide and Glipizide (Compound) resembles Chlorpropamide (Compound)